Life Long Learning Knowledge Assessment Course: Multi-Parametric Ultrasound in the Diagnosis of Prostate Cancer Webcast 011IC (2018)

Transrectal ultrasound is critical to biopsy guidance for the diagnosis of prostate cancer. However, ultrasound has the ability to improve diagnostic accuracy and may perform as well as multi-parametric MRI in identifying suspicious lesions. This course will familiarize participants with the multiparametric aspects of transrectal ultrasound including gray-scale ultrasound, color and power Doppler ultrasound, elastography, contrast-enhanced ultrasound as well as computer-enhanced transrectal ultrasound as modalities which alone or in combination may improve the diagnosis of prostate cancer.

This activity satisfies the AIUM requirement - "The physician should complete 10 hours of AMA PRA Category 1 Credits™ specific to genitourinary ultrasound every 3 years."

Target Audience

  • Urologists

Learning Objectives

After completing this activity, participants will be able to:

  1. Employ the physics behind each of the modalities of multi-parametric ultrasound.
  2. Identify the potential advantages and limitations of each of the modalities of multi-parametric ultrasound.
  3. Deploy the technology to improve the diagnosis of prostate cancer in appropriately selected populations of patients.
  4. Outline the additional resources and expertise necessary to use the modalities of multi-parametric ultrasound.
  5. Compare the efficacy of multiparametric ultrasound to that of multiparametric MRI.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
10/25/2018
Course expires: 
10/25/2021
List Price:
$99.00
Rating: 
0

COURSE DIRECTOR

Pat Fulgham, MD: Urology Clinics of North Texas: Investment Interest: Investment Interest

FACULTY

Tillman Loch, MD, PhD: DGU, EAU, Astellas PharmaGmbH, Glaxosmithkline IHCLimited, ANNA Technologies GmbH, CHINESE MEDICAL ASSOCIATION, Spr: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development; DGU, EAU, AUA, WJU: Other
Edouard Trabulsi, MD, FACS: GenomeDX: Consultant or Advisor; Janssen: Consultant or Advisor; Meeting Participant or Lecturer; Pfizer: Consultant or Advisor; Meeting Participant or Lecturer; Merck: Meeting Participant or Lecturer

 

PDF icon Education Council Disclosures

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: October, 2018
Expiration Date: October, 2021

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation

Price

List Price:
$99.00
Please login or register to take this course.